Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 14;13(4):281-286.
doi: 10.1055/s-0045-1802564. eCollection 2024 Oct.

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More

Prasad Narayanan  1 , Shyam Aggarwal  2 , Manish Singhal  3 , Vamshi Krishna  4 , A K Rathi  5 , Brig H P Singh  6 , Atul Sharma  7 , J B Sharma  8 , Amit Bhargava  9 , P Suresh  10 , Meenu Walia  7 , H S Darling  11 , K Medhi  12 , Kumardeep Dutta  7 , Sajjan Singh Rajpurohit  13 , Prashant Mehta  14 , Vikas Goswami  7 , Saumitra Rawat  15 , C Selvasekar  16 , Purvish M Parikh  17
Affiliations
Review

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More

Prasad Narayanan et al. South Asian J Cancer. .

Abstract

A significant number of patients with colorectal cancer (CRC) benefit from adjuvant therapy. While 6 months of FOLFOX is standard of care, newer regimens like CAPOX and SOX allow for shorter durations. Trials of importance include SCOT (U.K., Denmark, Spain, Sweden, Australia, New Zealand), TOSCA (Italy), Alliance/SWOG80702 (U.S., Canada), IDEA (France), ACHIEVE (Japan), and HORG (Greece). Management recommendation is also based on patient preferences, dividing them into fighters and fatalists. Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients-especially due to their limited mobility, comorbidities, and polypharmacy.

Keywords: MRD; ctDNA; drug metabolism; geriatric patients; overall survival; toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

None
Prasad Narayanan
See this image and copyright information in PMC

References

    1. ESMO Guidelines Working Group . Labianca R, Nordlinger B, Beretta G D et al.Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 06:vi64–vi72. - PubMed
    1. Schmoll H J, Tabernero J, Maroun J et al.Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III Special article Annals of Oncology 1106 | Sobrero et al. Volume 29 | Issue 5 | 2018 colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33(32):3733–3740. - PubMed
    1. André T, Boni C, Navarro M et al.Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. - PubMed
    1. Haller D G, Tabernero J, Maroun J et al.Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1471. - PubMed
    1. Kidwell K M, Yothers G, Ganz P A et al.Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012;118(22):5614–5622. - PMC - PubMed

LinkOut - more resources